In recent years scientific and technological advances have been made in development of ocular controlled drug delivery system to overcome physiological adversities of conventional dosage form. The present investigation was focused to prepare resinate of moxifloxacin and ion exchange resign to increase the residence time and decrease the solubility of drug in ocular site and incorporated in ocular insert. Ocular insert was prepared by solvent casting method. Nine formulations of OCDDS were prepared with different concentration of polymer (HPMC, MC, and PVA). Prepared formulation was subjected to physicochemical evaluation test,In vitro release, In vivo release and accelerated stability study test. In vivo release of formulation BRF6 was shown 98.87 % at the end of 12th hrs. In vitro release of all the formulation was computed with release kinetic model to predict release rate.suggested that all formulation was followed anomalous diffusion mechanism. Optimized formulation (BRF6) was subjected to antimicrobial test and sterility test. Result clearly showed it was passed. Accelerated stability study indicated optimized formulation was stable for longer period of time.
|Author||Ramesh Parmar and H. M. Tank|
|Number of Pages||84|
|Country of Manufacture||India|
|Product Brand||LAP LAMBERT Academic Publishing|
|Product Packaging Info||Box|
|In The Box||1 Piece|
|Product First Available On ClickOnCare.com||2015-07-31 00:00:00|